Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition.

Gallant JN, Sewell A, Almodovar K, Wang Q, Dahlman KB, Abramson RG, Kapp ME, Brown BT, Boyd KL, Gilbert J, Cohen DN, Yarbrough WG, Zhao Z, Lovly CM.

NPJ Precis Oncol. 2019 Feb 15;3:5. doi: 10.1038/s41698-019-0077-2. eCollection 2019.

2.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK.

JCI Insight. 2018 Jul 26;3(14). pii: 120422. doi: 10.1172/jci.insight.120422. eCollection 2018 Jul 26.

3.

Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition.

Johnson DB, Dahlman KB.

Clin Cancer Res. 2018 Dec 15;24(24):6107-6109. doi: 10.1158/1078-0432.CCR-18-1795. Epub 2018 Jul 24.

PMID:
30042206
4.

BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.

Doxie DB, Greenplate AR, Gandelman JS, Diggins KE, Roe CE, Dahlman KB, Sosman JA, Kelley MC, Irish JM.

Pigment Cell Melanoma Res. 2018 Nov;31(6):708-719. doi: 10.1111/pcmr.12712. Epub 2018 Jun 28.

PMID:
29778085
5.

Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum.

Dahlman KB, Weinger MB, Lomis KD, Nanney L, Osheroff N, Moore DE Jr, Estrada L, Cutrer WB.

Med Sci Educ. 2018 Mar;28(1):145-154. Epub 2018 Jan 2.

6.

Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma.

Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C.

J Surg Oncol. 2018 Feb;117(2):284-289. doi: 10.1002/jso.24834. Epub 2017 Sep 20.

PMID:
28940307
7.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.

8.

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN 3rd, Zent R, Clark PE.

Mol Oncol. 2017 Apr;11(4):405-421. doi: 10.1002/1878-0261.12044. Epub 2017 Mar 15. Erratum in: Mol Oncol. 2019 Apr;13(4):978.

9.

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J.

Invest New Drugs. 2017 Feb;35(1):95-104. doi: 10.1007/s10637-016-0406-z. Epub 2016 Nov 16.

10.

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS.

Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.

11.

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB.

Pigment Cell Melanoma Res. 2016 Jan;29(1):101-3. doi: 10.1111/pcmr.12394. Epub 2015 Aug 20. No abstract available.

PMID:
26176864
12.

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM.

Blood. 2015 Jul 23;126(4):508-19. doi: 10.1182/blood-2014-11-611194. Epub 2015 Jun 16.

13.

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS.

Oncogene. 2016 Mar 10;35(10):1225-35. doi: 10.1038/onc.2015.188. Epub 2015 Jun 15.

14.

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS.

Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15.

15.

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM.

Exp Hematol. 2015 Feb;43(2):74-8. doi: 10.1016/j.exphem.2014.10.009. Epub 2014 Oct 28.

16.

A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z.

Mol Cancer Ther. 2014 Jul;13(7):1918-28. doi: 10.1158/1535-7163.MCT-13-0804. Epub 2014 Apr 22.

17.

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.

Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL.

Breast Cancer Res Treat. 2014 Jun;145(2):389-99. doi: 10.1007/s10549-014-2945-3. Epub 2014 Apr 11.

18.

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W.

Clin Cancer Res. 2014 May 1;20(9):2264-75. doi: 10.1158/1078-0432.CCR-13-1591. Epub 2014 Mar 5. Review.

19.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

20.

Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers.

Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z.

Genome Med. 2013 Oct 11;5(10):91. doi: 10.1186/gm495. eCollection 2013.

21.

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.

Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W.

Genome Res. 2013 Sep;23(9):1434-45. doi: 10.1101/gr.152322.112. Epub 2013 Jun 3.

22.

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W.

Cancer Discov. 2012 Sep;2(9):791-7. Epub 2012 Jul 13.

23.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.

24.

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W.

PLoS One. 2012;7(4):e35309. doi: 10.1371/journal.pone.0035309. Epub 2012 Apr 20.

25.

Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.

Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL.

PLoS One. 2012;7(4):e34414. doi: 10.1371/journal.pone.0034414. Epub 2012 Apr 11.

26.

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS.

Nat Commun. 2012 Mar 6;3:724. doi: 10.1038/ncomms1727.

27.

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A.

Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475.

28.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB.

Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

Supplemental Content

Loading ...
Support Center